Sandoz Biosimilar Launch Timing May Hinge On Neupogen Patent Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen seeks court ruling that requirements of biosimilar statute are not optional as Sandoz claims; Sandoz says it does not have to wait until FDA approval to provide 180-day notice of its plans to launch.